The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC 2024 | Pirtobrutinib versus covalent BTKis and advice for managing toxicities
Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, speaks on the use of the non-covalent BTK inhibitor (BTKi) pirtobrutinib in comparison to covalent BTKis for the treatment of chronic lymphocytic leukemia (CLL). Ongoing trials are comparing pirtobrutinib to other BTKis; however, cross-trial comparisons indicate that pirtobrutinib may have a more favorable safety profile. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
